



European Monitoring Centre
for Drugs and Drug Addiction

Profile and trends of cannabis users admitted to treatment

Linda Montanari , Bruno Guarita


Prevalence and patterns of drug use among the general population (GPS)

Annual Expert Meeting – EMCDDA –


17-18 June 2014

Clients entering specialised drug treatment in Europe in 2012 by primary drug

All clients (n. 396 174)



New clients (n. 144 499)



■ Heroin ■ Cocaine ■ Stimulants ■ Cannabis ■ Other
 159 319 54 970 28 526 **109 399** 43 960


■ Heroin ■ Cocaine ■ Stimulants ■ Cannabis ■ Other
 31 215 26 200 11 844 **60 456** 14 784

Source: 2014 Statistical Bulletin

Notes: all clients: no data from LT; new clients: no data from LT, SE, NO

emcdda.europa.eu

Trend in estimated number of new clients entering treatment by selected primary drugs, 2006–2012




Source: 2014 Statistical Bulletin

emcdda.europa.eu



Trends 2002-2012 in new clients entering treatment for primary cannabis use

34 : 1 Joinpoint




- Increasing overall in Europe
- Significant change in 2005 ($p < 0.05$)
- Significant increase GE, GR, FR, UK
- Significant decrease in IT, LU, SI

Joinpoint regression:

- Trend analysis aimed to find the best-fit line 2002-2012
- Indicate significant change in trends ($p < 0.05$)
- Annual percent change (APC) and Average annual percent change (AAPC) emcdda.europa.eu

Proportion of new cannabis clients out of all drug clients in 2011



Source: Pilot data collection in 6 countries – TDI revision

emcdda.europa.eu

Data based on case definition TDI 3.0 - All clients

Profile of outpatient cannabis clients in 6 countries (1)

-Gender Ratio*: 4:1 (from 2.5 CZ to 6.3 in SP)
 (GPS) Daily users: 3:1
 (GPS) LYP: 2:1

-Mean age at treatment entry: 24 (from 19 in EE to 29 in NL)

-% cannabis users among <20 years drug clients: 83% (from 38% EE to 90% UK)

-Among cannabis clients : 92% 15-34 years
 (GPS) Daily users: 70%
 (GPS) LYP: 70%

Source: Pilot data collection in 6 countries – TDI revision

Year of treatment: 2011

emcdda.europa.eu

*Data based on case definition TDI ver 2.0/All clients



Profile of outpatient cannabis clients in 6 countries (2)

Mean age at first cannabis use:	16	(from 14 in EE to 17 in SP)
Lag time to treatment:	8 years	
5-10 years since first use:	25%	(from 25% NL to 45% PL)
>10 years since first use:	57%	(from 34% PL to 70% NL)
Daily cannabis users:	41%	(from 16% EE to 76% NL)
Occasional users:	20%	(from 11% NL to 40% EE)
Polydrug use*:	15%	Mainly Alcohol and Stimulants

Source: Pilot data collection in 6 countries – TDI revision

Year of treatment: 2011 Data based on case definition TDI ver 2.0

Polydrug use: data from CZ, NL, UK

Profile of outpatient cannabis clients in 6 countries (2)

Self-referrals:	35%	(from 31% UK to 100% EE)
Referred by the police:	25%	(from 3% CZ to 31% UK)
Living with family of origin:	50%	(from 25% - NL to 73% - PL)
Living in stable accommodation:	85%	(from 59% - CZ to 89% - SP)
Higher level of education:	64%	(from 59% PL to 80% EE)
Unemployed:	45%	(from 40% -UK to 75% -EE)
Student:	22%	(from 4% -NL to 33% -PL)

Source: Pilot data collection in 6 countries – TDI revision

Year of Treatment: 2011

Data based on case definition TDI ver 2.0 – All clients

UK: no data on living conditions, education

emcdda.europa.eu

Change in clients' profile (2002-2012)

- Increase in mean age (22.8 in 2002 to 24.3 in 2012)
- Decrease in mean age at first use (from 17.2 to 16.4)
- Gender ratio slightly changed from 4.4 to 4.9
- Cannabis use in combination with alcohol increased
- Number of daily users increased (from 3 423 to 17 000)

Source: Montanari, Zipfel et al. (2014) 2014 KBS conference

Issues

- Factors related to the increase (many and complex...)
 - Gender issue: higher M/F ratio among more intensive users
 - Age and age at first use
 - Daily users: increase but also many occasional?
 - Self-referred: what does it mean?
 - And what the role of the police?
- unemployed
- Highly educated: what the role of school and education?
 - 6-8 years before going to treatment: long time?
- Country differences
- Methodological limitations
 - Other issues???

Some EMCDDA references

<http://www.emcdda.europa.eu/activities/tdi>


<http://www.emcdda.europa.eu/topics/pods/frequent-cannabis-users>

<http://www.emcdda.europa.eu/publications/thematic-papers/daily-cannabis-use>

<http://www.emcdda.europa.eu/data/2014>

<http://www.emcdda.europa.eu/publications/monographs/cannabis>

<http://www.emcdda.europa.eu/html.cfm/index34898EN.html>



emcdda.europa.eu

THANK YOU!